Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92097 and following the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 2022, what plans he has to ensure that severely immunocompromised patients have access to Evusheld; and what estimate he has made of when the first patients will start to receive that treatment.

We are unable to provide the information requested as it is commercially sensitive. Any public announcement on the procurement of treatments would be made after an agreement is reached with companies. The Department is scoping the potential introduction of pre-exposure prophylaxis. This includes identification of the most appropriate patient groups which could benefit and the potential deployment and administration process. However, treatments must be clinically cost-effective and demonstrate sufficient efficacy against Omicron and new variants.